Previous in vitro studies conducted on GBM showed that SMAC mimetics used in cotreatment sensitized GBM cells to temozolomide or γ-irradiations.21, 22 A recent work described a reduction in U87MG tumor growth in an orthotopic mouse model when combined with Drozitumab, a TRAIL-R2 (Tumor-necrosis-factor-Related Apoptosis-Inducing Ligand Receptor 2).23 However, effect on survival of these combination treatments or SMAC mimetic alone was not evaluated in these studies. Here, TNFRSF10B is linked to glioblastoma.